OncoMatch/Clinical Trials/NCT03980002
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Is NCT03980002 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including FCR and Ibrutinib and BR and Ibrutinib for chronic lymphocytic leukemia.
Treatment: FCR and Ibrutinib · BR and Ibrutinib · Ibrutinib and Thalidomide — This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: combined chemotherapy (CHOP, COP)
Untreated with combined chemotherapy such as CHOP, COP and so on.
Cannot have received: chemotherapy regimens including fludarabine and bendamustine (fludarabine, bendamustine)
Unteated with chemotherapy regimens including fludarabine and bendamustine.
Cannot have received: BTK inhibitor (ibrutinib)
Unteated with Ibrutinib.
Lab requirements
Kidney function
serum creatinine ≤ 1.5 x upper limit of normal (ULN), unrelated to lymphoma
Liver function
AST and ALT ≤ 4.0 x upper limit of normal (ULN), bilirubin ≤ 2.0 x upper limit of normal (ULN)
Inadequate hepatic and renal function defined as: AST and ALT >4.0 x upper limit of normal (ULN), bilirubin >2.0 x upper limit of normal (ULN), Adequate renal function defined by serum creatinine >1.5 x upper limit of normal (ULN),unrelated to lymphoma.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify